ArticleArthritis research & therapy2020
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial.
Article in Arthritis research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02101333 (Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.Frontiers in immunology · 2023Pooled it
- Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Review
- Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.Frontiers in medicine · 2026Review
- Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis.Rheumatology advances in practice · 2025Article
- Difficult-to-treat Takayasu arteritis: a case-based review.Rheumatology international · 2024Review
- Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.Frontiers in medicine · 2024Article
- Advances and challenges in management of large vessel vasculitis.Rheumatology and immunology research · 2023Article
- Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.RMD open · 2023Article
- Animal models for large vessel vasculitis - The unmet need.Rheumatology and immunology research · 2023Review
- Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.Frontiers in immunology · 2023Review
- Development of severe colitis in Takayasu arteritis treated with tocilizumab.Clinical rheumatology · 2022Review
- Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.Heart and vessels · 2022Review
- The Th17 Pathway in Vascular Inflammation: Culprit or Consort?Frontiers in immunology · 2022Review
- Tocilizumab for faster and safer remission of Takayasu's arteritis.Therapeutic advances in chronic disease · 2022Article
- An Update on Childhood-Onset Takayasu Arteritis.Frontiers in pediatrics · 2022Review
- Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review.Therapeutic advances in musculoskeletal disease · 2021Article
- Giant cell arteritis versus Takayasu's Arteritis: Two sides of the same coin?Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess long-term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK).
methodsProspective open-labeled trial in naïve patients with TAK who received steroids at the dose of 0.7 mg/kg/day and 7 infusions of 8 mg/kg/month of tocilizumab. The primary endpoint was the number of patients who discontinued steroids after 7 infusions of tocilizumab. Secondary endpoints included disease activity and the number of relapses during 18-month follow-up.
resultsThirteen patients with TAK were included, with a median age of 32 years [19-45] and 12 (92%) females. Six (54%) patients met the primary end-point. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3, 4] at baseline, versus 1 [0-2] after 6 months; p < 0.001), ITAS-2010 score (5 [2-7] versus 3 [0-8]; p = 0.002), and ITAS-A score (7 [4-10] versus 4 [1-15]; p = 0.0001)]. During the 12-month follow-up after tocilizumab discontinuation, a relapse occurred among 5 patients (45%) out of 11 in which achieved remission after 6 months of tocilizumab.
conclusionTocilizumab seems an effective steroid sparing therapy in TAK, but maintenance therapy is necessary.
trial registrationClinicalTrials.gov NCT02101333 . Registered on 02 April 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.